2395 — Shin Nippon Biomedical Laboratories Share News
0.000.00%
Last trade - 00:00Table: Shin Nippon Biomedical -Q1 group results
Table: Shin Nippon Biomedical -2025/26 group results
Table: Shin Nippon Biomedical - 9-MTH group results
Table: Shin Nippon Biomedical -2025/26 group forecast
Table: Shin Nippon Biomedical - 6-MTH group results
Table: Shin Nippon Biomedical -Q1 group results
Table: Shin Nippon Biomedical -2024/25 group results
Subsidiary Satsuma Pharmaceuticals Received Us FDA Approval For Acute Migraine Treatment Atzumi (Sts101)
Table: Shin Nippon Biomedical - 9-MTH group results
Table: Shin Nippon Biomedical -Q1 group results
Table: Shin Nippon Biomedical -2023/24 group results
Table: Shin Nippon Biomedical - 9-MTH group results
US FDA declines to approve Shin Nippon Biomedical's migraine drug
Table: Shin Nippon Biomedical - 6-MTH group results
Table: Shin Nippon Biomedical -Q1 group results
Brief: Shin Nippon Biomedical Laboratories Ltd Results Of Tender Offer For All Outstanding Shares Of Satsuma Not Owned By Snbl And Change In Subsidiaries Upon Completion Of Transaction
Brief: Satsuma Pharmaceuticals Announces FDA Acceptance Of 505(B)(2) NDA For Sts101, A Novel And Investigational Dihydroergotamine Nasal Powder Product For The Acute Treatment Of Migraine
Table: Shin Nippon Biomedical -2022/23 group results
Commencement Of Tender Offer For Satsuma Pharmaceuticals, Inc In U.S.